Details of the Drug
General Information of Drug (ID: DM2OR8E)
Drug Name |
4-(4-methoxy-benzylideneamino)-benzenesulfonamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CHEMBL271911; N-(4-Methoxybenzylidene)-4-sulfamoylaniline; 66667-56-9; AC1LCE5G; CBDivE_014997; SCHEMBL1517619; 4-[(4-methoxyphenyl)methylideneamino]benzenesulfonamide; CTK1J4463; DTXSID70347792; MolPort-000-519-122; MLUHDVSELBSKPI-UHFFFAOYSA-N; MLUHDVSELBSKPI-MHWRWJLKSA-N; ZINC131008; BDBM50371762; STK790787; AKOS001583663; MCULE-9167737347; MCULE-3795342438; ST016434; 4-(4-Methoxybenzylideneamino)benzenesulfonamide; Benzenesulfonamide, 4-(4-methoxybenzylideneamino)-; 4-((4-METHOXYBENZYLIDENE)AMINO)BENZENESULFONAMIDE
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 290.34 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||